Effective as of October 3, 2023, each of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed to serve as members of Syra Health Corp.'s board of directors. In addition, effective as of October 3, 2023, each of Sherron Rogers, Ketan Paranjape and Avutu Reddy were appointed as members of the Company's audit committee, with Sherron Rogers serving as chair; Vijayapal Reddy and Avutu Reddy were appointed as members of the Company's compensation committee, with Avutu Reddy serving as chair; and Vijayapal Reddy and Avutu Reddy were appointed as members of the Company's nominating and corporate governance committee, with Vijayapal Reddy serving as chair. Each of Sherron Rogers, Ketan Paranjape, Avutu Reddy, Vijayapal Reddy and Andrew Dahlem is deemed an independent" director as such term is defined by the rules of The Nasdaq Stock Market LLC.

There are no family relationships between any of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy and any of other officers and directors. There is no arrangement or understanding between any of Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy and any other persons pursuant to which Sherron Rogers, Andrew Dahlem, Vijayapal Reddy, Ketan Paranjape, and Avutu Reddy were appointed as directors. Sherron Rogers: Ms. Rogers has over 19 years of senior leadership experience.

Since March 2022, Ms. Rogers has served as the Chief Financial Officer of Johns Hopkins All Children's Hospital. Previously, from August 2020 to March 2022, Ms. Rogers served as the Chief Financial Officer and Chief Strategy Officer of Eskenazi Healths. Prior to serving in those roles, Ms. Rogers served as the Vice President of Business Development and Operational Excellence and Strategy at Eskenazi Health.

In addition, from 2005 to 2016 Ms. Rogers served in a variety of leadership roles at Indiana University Health, including as Vice President and Transformation Officer, and from 2003 to 2005, Ms. Rogers served as a director and Lean Six Sigma Black Belt at Cummins Inc. Ms. Rogers holds a Master of Science degree in Information Science and a Bachelor of Arts degree in Psychology from Indiana University, Bloomington. The Company believes that Ms. Rogers is qualified to serve as a member of the Company's Board because of her experience in senior leadership roles and background in healthcare. Andrew M. Dahlem, PhD: Since November 2018, Dr. Dahlem has served as Senior Research Professor of Medicine at the Indiana University School of Medicine and also served as Chief of the Division of Clinical Pharmacology until May 2022.

Dr. Dahlem is co-founder and has served as an advisor to Gate Neurosciences, a biotechnology company focused on new therapies for treatment resistant depression, since April 2019 and President of Dr. Dahlem Consulting LLC, advising on the discovery and development of novel therapeutics for academia, biotech and the pharmaceutical industry since May 2018. Furthermore, Dr. Dahlem also served as Vice President of Research Operations and Chief Operating Officer of Lilly Research Laboratories and Lilly Research Laboratories Europe at Eli Lilly and Company until his retirement in December 2017. Moreover, Dr. Dahlem has served in various other capacities at Eli Lilly and Company including Vice President of Toxicology, Drug Disposition, Pharmacokinetics; Executive Director of Toxicology and Drug Disposition; Director of Drug Disposition and Biochemical Toxicology; Head of Biochemical Toxicology; and Senior Pharmacologist.

Dr. Dahlem holds a Doctor of Philosophy degree in Toxicology from the College of Veterinary Medicine at the University of Illinois at Urbana-Champaign and a Bachelor of Science degree from The Ohio State University. The Company believes that Dr. Dahlem is qualified to serve as a member of the Company's Board because of his medical background and diverse experience in biotechnology over more than 30 years. Vijayapal R. Reddy, DABT, DVM, PhD: Dr. Reddy is a drug development professional with over 30 years of experience in drug discovery and development in global pharmaceutical industry.

Since August 2017, Dr. Reddy has served as an advisor as well as a Director of VIPRA, LLC. Dr. Reddy currently serves as a consultant for various pharmaceutical, biotechnology and vaccine companies. From 2007 to 2017, Dr. Reddy served as a Senior Researcher Advisor/Executive Director at Lilly Research Laboratories, at Lilly.

Ketan Paranjape, PhD: Since April 2018, Dr. Paranjape has served as the Vice President of Roche Information Solutions, and since September 2020, he has served as the Vice President of Commercial Business Operations, Business Intelligence and Analytics at Roche Diagnostics, a multinational healthcare company. Since September 2019, Dr. Paranjape has been included on the World Health Organization's roster of digital health experts which was established to advise the World Health Organization Secretariat. Since June 2022, Dr. Paranjape has served as a member of the board of directors of Indy Chamber, a non-profit organization that is dedicated to economic development in the Indianapolis region.

Since September 2021, he has served on the Dean's Advisory Council at Indiana University's Luddy School of Informatics, Computing, and Engineering, and since February 2021, he has served as Advisory Board Member at the University of Wisconsin-Madison, Department of Electrical and Computer Engineering. Since February 2021, he has also been a member of the digital health executive leadership group at AdvaMed. Dr. Paranjape holds a Doctor of Philosophy degree in Artificial Intelligence in Healthcare from Amsterdam University Medical Center, a Master of Business Administration degree from the University of Oregon, a Master of Science degree in Electrical and Computer Engineering from the University of Wisconsin-Madison and a Bachelor of Science degree in Electrical Engineering from the University of Pune.

The Company believes that Dr. Paranjape is qualified to serve as a member of the Company's Board because of his engineering and commercial background and experience in advisory roles, technology and product development. Avutu S. Reddy, PhD: Dr. Reddy has over 20 years of leadership experience in both in research and development and business. Since October 2017, Dr. Reddy has served as the Strategic Scientific and Emerging Business Intelligence Leader at Corteva Agriscience.; Competitive Intelligence Leader from January 2009 to December 2017; Dr. Reddy holds a Doctor of Philosophy degree and Master of Science from Acharya Nagarjuna University, a Master of Education degree from Annamalai University and Bachelor of Science and Bachelor of Education degrees from S.V. University.